RecruitingNot ApplicableNCT06854458

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study


Sponsor

Brigham and Women's Hospital

Enrollment

1,000 participants

Start Date

Jun 27, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.


Eligibility

Min Age: 35 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blood draw for the laboratory assessment, a drug called Gadavist, and others for people with cardiac magnetic resonance imaging, ischemic heart disease (ihd), and other related conditions. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 35 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTQuantitative Myocardial Blood Flow Evaluation

The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.

DIAGNOSTIC_TESTQualitative Myocardial Blood Flow Evaluation

The perfusion sequence will not produce additional quantitative perfusion maps.

DRUGGadavist

Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).

DRUGVasodilator

All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).

DIAGNOSTIC_TESTBlood draw for the laboratory assessment

A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.


Locations(12)

University of California San Francisco

San Francisco, California, United States

UofL Health - Heart Hospital

Louisville, Kentucky, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

St. Francis Hospital and Heart Center

Roslyn, New York, United States

Atrium Health - Sanger Heart & Vascular Institute

Charlotte, North Carolina, United States

Cleveland Clinic

Cleveland, Ohio, United States

The Ohio State University

Columbus, Ohio, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Houston Methodist Hospital

Houston, Texas, United States

University of Virginia

Charlottesville, Virginia, United States

Virginia Commonwealth University

Richmond, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06854458


Related Trials